# Levetiracetam

## Keppra inj 500mg/5mL

| TAH Drug Code      | [IKEP](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IKEP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The following epilepsy patients are temporarily unsuitable or unable to be treated with oral anti-epileptic drugs: 1.Monotherapy for partial epileptic seizures (with or without secondary generalized seizures) in patients over 16 years of age. 2.Adjuvant therapy for partial epileptic seizures (with or without secondary generalized seizures) in children over 4 years old or adult， myoclonic epileptic seizures in adolescents over 12 years old and adult， and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy in adolescents over 12 years old and adults.                                                                                                                                                                                                                                                                       |
| Dosing             | Monotherapy: Adults， 16 Years and Older: Initial， 250 mg twice daily IV/orally; titration， may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum 3000 mg/day. Adjunctive therapy: Adults， 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily， increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Hypersensitivity to levetiracetam.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | Common Gastrointestinal: Loss of appetite (3% to 8% )， Vomiting (15% ) Immunologic: Infectious disease (13% ) Musculoskeletal: Decreased bone mineral density (70% )， Neck pain (2% to 8% ) Neurologic: Asthenia (15% )， Dizziness (5% to 9% )， Headache (14% to 19% ) Psychiatric: Abnormal behavior (7% to 37.6% )， Irritability (6% to 12% ) Respiratory: Cough (2% to 9% )， Nasopharyngitis (7% to 15% ) Other: Fatigue (10% to 11% ) Serious Dermatologic: Stevens-Johnson syndrome， Toxic epidermal necrolysis due to drug Hematologic: Decreased erythrocyte production， Decreased white blood cell count (2.4% to 3.2% )， Eosinophil count raised (8.6% )， Neutropenia ( 2.4% )， Pancytopenia， Thrombocytopenia Hepatic: Liver failure Immunologic: Anaphylaxis Neurologic: Somnolence (8% to 45% ) Psychiatric: Suicidal intent (0.5% )， Suicide Other: Angioedema |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| More Info          | [UpToDate](https://www.uptodate.com/contents/levetiracetam-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

## Keppra solution 100mg/mL， 300mL

| TAH Drug Code      | [LKEP](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=LKEP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1.Monotherapy for partial epileptic seizures (with or without secondary generalized seizures) in patients over 16 years of age. 2.Adjuvant therapy for partial epileptic seizures (with or without secondary generalized seizures) in children over 4 years old or adult， myoclonic epileptic seizures in adolescents over 12 years old and adult， and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy in adolescents over 12 years old and adults.                                                                                                                                                                                       |
| Dosing             | Monotherapy: Adults， 16 Years and Older: Initial， 250 mg twice daily IV/orally; titration， may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum 3000 mg/day. Adjunctive therapy: Adults， 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily， increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily.                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to levetiracetam.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Adverse Effects    | Common: Loss of appetite (3-8%)， Vomiting (15%)， Infectious disease (13%)， Decreased bone mineral density (70%)， Neck pain (2-8%)， Asthenia (15%)， Dizziness (5-9%)， Headache (14-19%)， Abnormal behavior (7-37.6%)， Irritability (6-12%)， Cough (2-9%)， Nasopharyngitis (7-15%)， Fatigue (10-11%) Serious: Stevens-Johnson syndrome (SJS)， Toxic epidermal necrolysis (TEN)， Decreased erythrocyte production， Decreased white blood cell count (2.4-3.2%)， Eosinophil count above reference range (8.6%)， Neutropenia ( 2.4%)， Pancytopenia， Thrombocytopenia， Liver failure， Anaphylaxis， Somnolence (8-45%)， Suicidal intent (0.5%)， Suicide， Angioedema |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/levetiracetam-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

## Keppra 500mg

| TAH Drug Code      | [OKEP](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OKEP)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1.Monotherapy for partial epileptic seizures (with or without secondary generalized seizures) in patients over 16 years of age. 2.Adjuvant therapy for partial epileptic seizures (with or without secondary generalized seizures) in children over 4 years old or adult， myoclonic epileptic seizures in adolescents over 12 years old and adult， and primary generalized tonic-clonic seizures associated with idiopathic generalized epilepsy in adolescents over 12 years old and adults.                                                                                                                                                                                                                                                                                                                              |
| Dosing             | Monotherapy: Adults， 16 Years and Older: Initial， 250 mg twice daily IV/orally; titration， may increase by increments of 500 mg/day every 2 weeks in 2 divided doses to maximum: 3000 mg/day. Adjunctive therapy: Adults， 18 Years and Older; 12-17 years older with weighing >50 kg : Initial: 1000 mg on Day1 (500mg twice daily); increase or decrease every 2-4 weeks by 1 g/day based on response and tolerability to a maximum of 3 g once daily. 4-11 years old children and 12-17 years old with weighing <50 kg: Initial: 10 mg/kg twice daily， increase/decrease 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily. Child >6 years and dosage <250mg should use solution of Levetiracetam.                                                                                       |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Contraindications  | Hypersensitivity to levetiracetam.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common: Loss of appetite (3-8%)， Vomiting (15%)， Infectious disease (13%)， Decreased bone mineral density (70%)， Neck pain (2-8%)， Asthenia (15%)， Dizziness (5-9%)， Headache (14-19%)， Abnormal behavior (7-37.6%)， Irritability (6-12%)， Cough (2-9%)， Nasopharyngitis (7-15%)， Fatigue (10-11%). Serious: Stevens-Johnson syndrome， Toxic epidermal necrolysis， Decreased erythrocyte production， Decreased white blood cell count (2.4-3.2%)， Eosinophil count above reference range (8.6%)， Neutropenia ( 2.4%)， Pancytopenia， Thrombocytopenia， Liver failure， Anaphylaxis， Drug reaction with eosinophilia and systemic symptoms， Somnolence (8-45%)， Suicidal intent (0.5%)， Suicide， Angioedema. [仿單]罕見：Obsessive-compulsive disorder， neuroleptic malignant syndrome(20241226新增) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/levetiracetam-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

